Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-24-024704
Filing Date
2024-10-03
Accepted
2024-10-03 20:30:10
Documents
1
Period of Report
2024-10-01

Document Format Files

Seq Description Document Type Size
1 form4-10032024_081007.html 4  
1 form4-10032024_081007.xml 4 9710
  Complete submission text file 0001415889-24-024704.txt   11296
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Issuer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA 4TH FLOOR, PO BOX 142904 AMMAN M2 11844
Business Address
Haddadin Yezan Munther (Reporting) CIK: 0001718004 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37759 | Film No.: 241353305